Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lymphoma × pegfilgrastim × Clear all

Phase

Phase 2 18 Phase 3 4 Phase 1/2 4 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Neutropenia 3 Lymphoma, Non-Hodgkin 2 Ovarian Neoplasms 1 Malignant Solid Tumors 1 Lymphoma 1 Lung Neoplasms 1 Fever 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pegylated granulocyte colony-stimulating factor 3 entecavir 3 Granulocyte Colony-Stimulating Factor 3 Cyclophosphamide 3 Aprepitant 3 Prednisolone 2 Dexamethasone 2 Brentuximab Vedotin 2 rasburicase 1 prednylidene 1 plerixafor 1 peginterferon alfa-2b 1 pegfilgrastim 1 golimumab 1 fludarabine phosphate 1 fludarabine 1 fluarix 1 ferrous succinate 1 dexamethasone 21-phosphate 1 arexvy 1 abrysvo 1 Zidovudine 1 Water 1 Watchful Waiting 1 Vindesine 1 Vincristine 1 Vinblastine 1 Valproic Acid 1 Urate Oxidase 1 Tropisetron 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02805218 2016-06-20

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡